Onkologie. 2013:7(1):30-34

Immunotherapy of bladder cancer

Milan Král, Zdeněk Mucha, Vladimír Študent
Urologická klinika LF UP a FN Olomouc

The aim of this article is to present current recommendations for treatment of bladder cancer after initial transurethral resection of tumor.

Adjuvant intravesical treatment with chemotherapy and immunotherapy unequivocally lowers cancer recurrence and in case of

maintenance immunotherapy even more prolongs the time to bladder cancer progression. Therefore it plays an irreplaceable role in

complex care of non-muscle invasive bladder cancer patients.

Keywords: bladder cancer, chemotherapy, immunotherapy, treatment failure

Published: February 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Král M, Mucha Z, Študent V. Immunotherapy of bladder cancer. Onkologie. 2013;7(1):30-34.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. J Urol. 2009; 27(3): 289-293. Go to original source... Go to PubMed...
    2. Pešl M, Soukup V, Babjuk M, Dundr P, Capoun O, Valová Z. Hodnocení významu klinicko-patologických prognostických faktorů u nádorů močového měchýře neinfiltrujících svalovinu. Ces Urol 2011; 15(4): 222-228.
    3. Sylvester RJ, van der Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DWW, and Kurth KH. Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials. Eur Urol 2006; 49(3): 466-477. Go to original source... Go to PubMed...
    4. Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pi?eiro L, Gonzalez M, Portillo J, Ojea A, Pertusa C, Rodriguez-Molina J, Camacho JE, Rabadan M, Astobieta A, Montesinos M, Isorna S, Munta?ola P, Gimeno A, Blas M, Martinez-Pi?eiro JA. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009; 182(5): 2195-2203. Go to original source... Go to PubMed...
    5. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, Roupr?t M; European Association of Urology (EAU). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 2011; 59(6): 997-1008. Go to original source... Go to PubMed...
    6. Sylvester RJ, Oosterlinck W, Witjes JA. The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol. 2008 Apr; 53(4): 709-719. Go to original source... Go to PubMed...
    7. Hendricksen K, Witjes WP, Idema JG, Kums JJ, van Vierssen Trip OB, de Bruin MJ, Vergunst H, Caris CT, Janzing-Pastors MH, Witjes JA. Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer. Eur Urol. 2008; 53(5): 984-991. Go to original source... Go to PubMed...
    8. Böhle A, Brandau S. Immune mechanisms in bacillus Calmette-Guérin immunotherapy for superficial bladder cancer. J Urol 2003; 170: 964-969. Go to original source... Go to PubMed...
    9. Babjuk M. Nádory močového měchýře. In: Dvořáček J. et al. Onkourologie. Galén, 2005: 139-173.
    10. Campbell´s Urology. 10th Edition, Philadelphia. s. 2342-2349.
    11. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000; 163(4): 1124-1129. Go to PubMed...
    12. van der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV. EORTC Genito-Urinary Tract Cancer Group. Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol. 2003; 44(4): 429-434. Go to original source... Go to PubMed...
    13. Sylvester RJ, van der Meijden AP, Lamm DL.Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002; 168(5): 1964-1970. Go to original source... Go to PubMed...
    14. Böhle A, Bock PR. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004; 63(4): 682-686; discussion 686-687. Go to original source... Go to PubMed...
    15. Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006; 67(6): 1216-1223. Go to original source... Go to PubMed...
    16. Babjuk M, Soukup V. Intravezikální léčba povrchových nádorů močového měchýře. Urolog. Pro praxi 2004; 3: 116-120.
    17. Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Calais Da Silva F, Powell PH, Prescott S, Kirkali Z, van de Beek C, Gorlia T, de Reijke TM. EORTC Genito-Urinary Tract Cancer Group. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010; 57(5): 766-773. Go to original source... Go to PubMed...
    18. Ojea A, Nogueira JL, Solsona E, Flores N, Gómez JM, Molina JR, Chantada V, Camacho JE, Pi?eiro LM, Rodríguez RH, Isorna S, Blas M, Martínez-Pi?eiro JA, Madero R. CUETO Group (Club Urológico Espa?ol De Tratamiento Oncológico). A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol 2007; 52(5): 1398-1406. Go to original source... Go to PubMed...
    19. Damiano R, De Sio M, Quarto G, Di Lorenzo G, Perdon? S, Palumbo IM, Azzarito G, Giugliano F, Autorino R. Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Guérin-induced toxicity? BJU Int 2009; 104(5): 633-639. Go to original source... Go to PubMed...
    20. SPC Immucyst (příbalový leták preparátu). http://www.sanofipasteur.cz/sanofi-pasteur2/sp-media/SP_CZ/CS/124/913/SPC%20Immucyst%2006%2005%202009.pdf.
    21. Lamm D, van der Meijden P, Morales A, Brosman S, Catalona W, Herr W. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 1992; 147(3): 596-600. Go to original source... Go to PubMed...
    22. Anastasiadis A, de Reijke TM. Best practice in the treatment of nonmuscle invasive bladder cancer. Ther Adv Urol 2012; 4(1): 13-32. Go to original source... Go to PubMed...
    23. Havránek O, Krhut J, Němec D, Král R, Haring Z. Komplikace intravezikální terapie svalovinu neinfiltrujícího uroteliálního karcinomu močového měchýře vakcínou bacillus Calmette-Guerine (BCG). Ces Urol 2010; 14(2): 92-98.
    24. Dušek P, Hyršl I, Kawaciuk I. Nežádoucí účinky imunoterapie povrchových nádorů močového měchýře BCG vakcínou. Ces Urol 1999; 3(3): 35-38.
    25. Dvořák T, Schraml J, Hynek V, Hálek M, Sapkota K, Kunec F, Broul M, Sticová E. Oboustranná granulomatózní orchiepididymitis jako komplikace BCG léčby povrchového karcinomu močového měchýře. Urolog pro Praxi 2007; 8(4): 180-181.
    26. Herr HW, Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol 2003; 169(5): 1706-1708. Go to original source... Go to PubMed...
    27. van den Bosch S, Alfred Witjes J. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol 2011; 60(3): 493-500. Go to original source... Go to PubMed...
    28. Di Lorenzo G, Perdon? S, Damiano R, Faiella A, Cantiello F, Pignata S, Ascierto P, Simeone E, De Sio M, Autorino R. Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer 2010; 116(8): 1893-1900. Go to original source... Go to PubMed...
    29. Addeo R, Caraglia M, Bellini S, Abbruzzese A, Vincenzi B, Montella L, Miragliuolo A, Guarrasi R, Lanna M, Cennamo G, Faiola V, Del Prete S. Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol 2010; 28(4): 543-548. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.